Analytical Data
-
基因名
S100A1
-
简介
S100A1 is a small calcium-binding protein that plays critical roles in multiple processes, including Ca(2+) homeostasis and cardiomyocyte regulation. Elevated intracellular Ca(2+) triggers conformational changes in S100A1, thereby interacting with key proteins in cardiomyocytes such as RYR1, RYR2, ATP2A2 and F1-ATPase. S100A1 Protein, Human (His) is the recombinant human-derived S100A1 protein, expressed by E. coli , with N-His labeled tag.
- Application
-
别名
Protein S100-A1; S-100 protein alpha chain; S100A; S100A1; S100-alpha
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P23297
-
表达区间
M1-S94
-
蛋白长度
Full Length
-
分子量
11.5 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
S100A1 is a member of the S100 protein family, characterized by its ability to bind calcium and zinc ions, playing a crucial role in various cellular processes, including cell cycle regulation, differentiation, and apoptosis. Research into S100A1 has gained momentum due to its involvement in multiple pathophysiological conditions, such as cardiac hypertrophy, neurodegenerative diseases, and cancer. As a cardiomyocyte-specific protein, S100A1 has been implicated in regulating cardiac contractility and calcium handling, making it a potential therapeutic target for heart disease. The recombinant protein form of S100A1 allows for in-depth studies of its biochemical properties, interactions, and roles in signal transduction pathways. By producing S100A1 through recombinant techniques, researchers can obtain high-purity proteins for functional assays, therapeutic applications, and structural studies, facilitating a better understanding of its mechanisms in health and disease. Recent advancements in recombinant DNA technology have further enabled the exploration of S100A1 as a biomarker or therapeutic agent, emphasizing its importance in translational research. Thus, the study of recombinant S100A1 not only broadens our understanding of its biological functions but also opens new avenues for developing targeted treatments for diseases associated with its dysregulation.
